# Study of Oral Fampridine-SR in Multiple Sclerosis

> **NCT00127530** · PHASE3 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 300 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Fampridine-SR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00127530
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2006-06
- **Final completion:** 2006-09
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2018-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127530, "Study of Oral Fampridine-SR in Multiple Sclerosis". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00127530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*